Equity Overview
Price & Market Data
Price: $48.00
Daily Change: +$0.30 / 0.62%
Daily Range: $46.48 - $48.75
Market Cap: $4,896,357,888
Daily Volume: 1,135,859
Performance Metrics
1 Week: 2.87%
1 Month: 4.23%
3 Months: 20.59%
6 Months: 39.53%
1 Year: 22.61%
YTD: 8.97%
Company Details
Employees: 196
Sector: Health technology
Industry: Biotechnology
Country:
Details
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.